New Intelligence Tool to Help Cut Down on Late Nights for Drug Development Scientists
Hanson Wade has launched Beacon Targeted Therapies to classify and clarify data to support drug development decision making.
LONDON, September 21, 2017 (Newswire.com) - Hanson Wade, the London-based life sciences knowledge services specialist, has launched Beacon Targeted Therapies (www.beacon-intelligence.com) to create clarity for scientists struggling to make sense of the vast volumes of unstructured clinical and preclinical drug development data.
Beacon Targeted Therapies specializes in curating data and intelligence in targeted therapies and targeted therapies alone, using a team of scientists to standardize, classify and clarify data to support drug development decision-making.
The first data module available with Beacon Targeted Therapies addresses antibody-drug conjugates and is being launched at the World ADC Conference in San Diego today. An IO Combination data set is set to follow in October, with Immune Checkpoint Modulator monotherapies in November. 2018 is set to see further data sets added to the platform based on areas of targeted therapy development where the growth of data is high and the need for accurate, robust and timely intelligence is crucial.
Hanson Wade researchers curate data from the widest range of sources including trial registries, academic papers, company presentations, conferences and much, much more.
Beacon early adopter Tim Lowinger, Chief Scientific Officer with Boston-based Mersana Therapeutics said, “I find Beacon intelligence to be very customer focused and a pleasure to work with. The Beacon database has become a very valuable resource for me as I strive to keep up with the latest developments in the field.”
Media Inquires: Andy Cook [email@example.com]
Source: Hanson Wade
Categories: Pharmaceuticals and Biotech